• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

    7/30/24 12:47:55 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    SC 13G/A 1 d860329dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Rallybio Corporation

    (Name of Issuer)

    COMMON STOCK, $0.0001 PAR VALUE PER SHARE

    (Title of Class of Securities)

    75120L 100

    (CUSIP Number)

    July 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 75120L 100    SCHEDULE 13G/A    Page 2 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Canaan XI L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     2,058,217

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     2,058,217

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,058,217

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.97% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    The percent of class was calculated based on 41,449,297 shares of common stock outstanding as of May 6, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on May 9, 2024.


    CUSIP No. 75120L 100    SCHEDULE 13G/A    Page 3 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Canaan Partners XI LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     2,058,217

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     2,058,217

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,058,217

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.97% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    (1)

    The percent of class was calculated based on 41,449,297 shares of common stock outstanding as of May 6, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on May 9, 2024.


    CUSIP No. 75120L 100    SCHEDULE 13G/A    Page 4 of 6 Pages

     

    Item 1.       Issuer
       (a)    Name of Issuer:
          Rallybio Corporation (the “Issuer”)
       (b)    Address of Issuer’s Principal Executive Offices:
         

    234 Church Street

    Suite 1020

    New Haven, CT 06510

    Item 2.       Filing Person
      

    (a) –

    (c)

       Name of Persons Filing; Address; Citizenship:
         

    (i) Canaan XI L.P., a Cayman Islands limited partnership (the “Fund”); and

     

    (ii)  Canaan Partners XI LLC, a Delaware limited liability company (the “General Partner”).

     

    The address of the principal business office of each of the reporting persons is 2765 Sand Hill Road, Menlo Park, CA 94025.

       (d)    Title of Class of Securities:
          Common stock, $0.0001 par value per share, (the “Common Stock”)
       (e)   

    CUSIP Number:

     

    75120L 100

    Item 3.    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under Section 15 of the Act;
       (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
       (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
       (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
       (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    CUSIP No. 75120L 100    SCHEDULE 13G/A    Page 5 of 6 Pages

     

    Item 4.

    Ownership.

    (a) and (b) Amount beneficially owned:

    (i) The Fund directly owns 2,058,217 shares of Common Stock, which represents approximately 4.97% of the outstanding shares of Common Stock.

    (ii) The General Partner is the general partner of the Fund and may be deemed to beneficially own 2,058,217 shares of Common Stock, which represents approximately 4.97% of the outstanding shares of Common Stock.

    (c) Number of shares as to which such person has:

     

         Number of Shares of Common Stock  
    Reporting Person    (i)      (ii)      (iii)      (iv)  

    Canaan XI L.P.

         2,058,217        0        2,058,217        0  

    Canaan Partners XI LLC

         2,058,217        0        2,058,217        0  

     

    (i)

    Sole power to vote or direct the vote

     

    (ii)

    Shared power to vote or to direct the vote

     

    (iii)

    Sole power to dispose or to direct the disposition of

    (iv) Shared power to dispose or to direct the disposition of

    The percent of class was calculated based on 41,449,297 shares of common stock outstanding as of May 6, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on May 9, 2024.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☒

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 75120L 100    SCHEDULE 13G/A    Page 6 of 6 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: July 30, 2024

     

    CANAAN XI L.P.
    By:   CANAAN PARTNERS XI LLC, its General Partner
    By:  

    /s/ Nancy Levenson

      Nancy Levenson, Attorney-in-Fact
    CANAAN PARTNERS XI LLC
    By:  

    /s/ Nancy Levenson

      Nancy Levenson, Attorney-in-Fact
    Get the next $RLYB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Financials

    Live finance-specific insights

    See more
    • Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

      -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

      12/20/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

      – On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th

      5/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi

      4/29/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

      – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the inability of the R

      4/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      11/12/24 10:34:15 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rallybio Corporation

      SC 13G - Rallybio Corp (0001739410) (Subject)

      7/30/24 9:06:36 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      7/30/24 12:47:55 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rallybio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Rallybio from Buy to Neutral

      4/9/25 8:36:28 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by JP Morgan

      JP Morgan downgraded Rallybio from Overweight to Neutral

      5/15/24 7:39:44 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by Jefferies with a new price target

      Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

      2/7/24 6:42:56 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Uden Stephen

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:30:54 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ryder Steven

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:29:06 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Lieber Jonathan I

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:27:18 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

      -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

      6/29/23 7:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

      -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

      3/6/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

      1/31/23 4:05:00 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    SEC Filings

    See more
    • SEC Form S-8 filed by Rallybio Corporation

      S-8 - Rallybio Corp (0001739410) (Filer)

      5/9/25 4:06:03 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rallybio Corporation

      10-Q - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:22:09 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:14:12 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care